TFDA has officially approved ologen™ Collagen Matrix; this marks another chapter for ologen, along with more than 40 countries which are currently facilitating ologen treatments.
This author has yet to write their bio.Meanwhile lets just say that we are proud aeonastron_ad contributed a whooping 29 entries.
Entries by aeonastron_ad
A long-term study conducted in South Korea with a total of 26 areas of 25 eyes in 25 patients were carried out. Post-operative follow-up of 8-12 months concluded that no eyes showed recurrence or specific complications related to Ologen such as implant extrusion or allergic reaction. Minor complications such as flap vessel engorgement and flap […]
This study included a total of 20 eyes of 20 glaucoma patients, who were followed for at least 1-year after undergoing AGV implantation. In 12 eyes of 12 patients, conventional AGV (CAGV) surgery was performed, while in 8 eyes of 8 patients, ologen-augmented AGV (OAGV) implantation was performed. The rate of complete success was significantly […]
ologen™ CM Patch Grafts Improve Ahmed Valve Treatment Success Rates by 127% According to a new 6-month Korean study published in the journal Investigative Ophthalmology & Visual Science, success rates of Ahmed Glaucoma Valve (AGV) surgeries soar and post-operative anti-glaucoma medication needs drop when said surgeries are performed in combination with biodegradable collagen patch […]
5-Year MMC vs. ologen™ CM Study finds the latter with 37% Higher Success Rates A new study published in the Journal of Ophthalmology in May finds that using collagen matrix implants (available commercially as ologen™ CM) in place of mitomycin C (MMC) can significantly increase the long-term (5 year) success rates of open-angle glaucoma […]
A meta-analysis on ologen™ Collagen Matrix vs MMC in Trabeculectomy to be highlighted at the 2014 AGS Exhibit A meta-analysis on ologen™ Collagen Matrix vs. MMC in trabeculectomy by Miao He et al. (2014) will be highlighted during the exhibit of AAE at the 2014 AGS, Washington DC at Omni Shoreham Hotel from Feb 27 – Mar […]
New Horizons: “Novel Applications for ologen™ Collagen Matrix” at the 5th WGC, July 2013, Vancouver, Canada The Aeon Astron sponsored symposium “New Horizons: Novel Applications for ologen™ Collagen Matrix” held at the fifth World Glaucoma Congress, Vancouver, met with great success. The symposium featured the US experience with ologen™ Collagen Matrix (Dr David Godfrey, Glaucoma […]
India as leading country in the application of ologen™ Collagen Matrix and its combined use 2013 APAO-AIOS symposia recognize India as leading country in the application of ologen™ Collagen Matrix and its combined use with other compounds. The Aeon Astron sponsored symposium at the 2013 APAO-AIOS Joint Congress1 “Breakfast Debate: ologen™ Collagen Matrix or MMC for Glaucoma […]
EuroTimes And EyeWorld News on ologen™ Collagen Matrix ologen™ Collagen Matrix as An Alternative to MMC And The Patch Grafts in Glaucoma Surgery The monthly magazine of ESCRS1, EuroTimes (Vol 17; 11, Nov 2012), and the official news magazine of ASCRS2, EyeWorld (Vol 17; 9, Sept 2012), cover the news on ologen™ Collagen Matrix […]
Expansive applications of ologen™ Collagen Matrix in eye tissue repair and grafting widely discussed at 2012 EGS At the 10th European Glaucoma Society Congress in Copenhagen (June 17 – 22, 2012 ), Prof. T.S. Dietlein (Germany) and Dr. Hans J. Schuitmaker (The Netherlands) called for the need of ready-to-use anti-fibrotics and tissue repair grafting in […]
Aeon Astron Europe B.V. was incorporated in February 2008 in Leiden, the Netherlands.
Aeon Astron Europe B.V.
J.H. Oortweg 19, 2333 CH Leiden, The Netherlands
Tel:+31 71 332 2280
- ologen Collagen Matrix useful in controlling fibrosis response from Strabismus surgeries, new study finds.
- New Brazilian study finds combined use of ologen and MMC in Phaco-NPDS to provide significant clinical advantages
- ologen™ Collagen Matrix has been approved by Taiwan Food and Drug Administration (TFDA).